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STUDY QUESTION: Can we use prediction modelling to estimate the impact of coronavirus disease 
2019 (COVID 19) related delay in starting IVF or ICSI in different groups of women?
SUMMARY ANSWER: Yes, using a combination of three different models we can predict the impact of 
delaying access to treatment by 6 and 12 months on the probability of conception leading to live birth 
in women of different age groups with different categories of infertility. 
WHAT IS KNOWN ALREADY: Increased age and duration of infertility can prejudice the chances of 
success following IVF, but couples with unexplained infertility have a chance of conceiving naturally 
without treatment whilst waiting for IVF. The worldwide suspension of IVF could lead to worse 
outcomes in couples awaiting treatment, but it is unclear to what extent this could affect individual 
couples based on age and cause of infertility.
STUDY DESIGN, SIZE, DURATION: A population based cohort study based on national data from all 
licensed clinics in the UK obtained from the Human Fertilisation and Embryology Authority Register. 
Linked data from 9589 women who underwent their first IVF or ICSI treatment in 2017 and consented 
to the use of their data for research were used to predict livebirth numbers. 
PARTICIPANTS/MATERIALS, SETTING, METHODS: Three prediction models were used to estimate the 
chances of livebirth associated with immediate treatment versus a delay of 6 and 12 months in couples 
about to embark on IVF or ICSI. 
MAIN RESULTS AND THE ROLE OF CHANCE: We estimated that a 6-month delay would reduce 
livebirths by 0.4%, 2.4%, 5.7%, 9.5% and 11.8% in women aged <30, 30-35, 36-37, 38-39 and 40-42 
years, respectively, while corresponding values associated with a delay of 12 months were 0.9%, 4.9%, 
11.9%, 18.8% and 22.4%, respectively. In women with known causes of infertility, worst case (best 
case) predicted chances of livebirth after a delay of 6 months in women aged <30, 30-35, 36-37, 38-
39 and 40-42 years varied between 31.6% (35.0%), 29.0% (31.6%), 23.1% (25.2%), 17.2%  (19.4%) and 














11.3% (14.1%) for male factor infertility. The corresponding values in those treated immediately were 
31.7%, 29.8%, 24.5%, 19.0% and 11.7% for tubal factor and 34.4%, 32.4%, 26.7%, 20.2% and 12.8 % in 
male factor infertility. In women with unexplained infertility the predicted chances of livebirth after a 
delay of 6 months followed by one complete IVF cycle were 41.0%, 36.6%, 29.4%, 22.4% and 15.1% in 
women aged <30, 30-35, 36-37, 38-39 and 40-42 years, respectively, compared to 34.9%, 32.5%, 
26.9%, 20.7% and 13.2% in similar groups of women treated without any delay. The additional waiting 
period, which provided more time for spontaneous conception, was predicted to increase the relative 
number of babies born by 17.5%, 12.6%, 9.1%, 8.4% and 13.8%, in women aged <30, 30-35, 36-37, 38-
39 and 40-42 years, respectively.  A 12-month delay showed a similar pattern in all subgroups.
LIMITATIONS, REASONS FOR CAUTION: Major sources of uncertainty include the use of prediction 
models generated in different populations and the need for a number of assumptions. Although the 
models are validated and the bases for the assumptions are robust, it is impossible to eliminate the 
possibility of imprecision in our predictions. Therefore, our predicted live birth rates need to be 
validated in prospective studies to confirm their accuracy.
WIDER IMPLICATIONS OF THE FINDINGS: A delay in starting IVF reduces success rates in all couples. 
For the first time, we have shown that while this results in fewer babies in older women and those 
with a known cause of infertility, it has a less detrimental effect on couples with unexplained infertility, 
some of whom conceive naturally whilst waiting for treatment. Post COVID 19, clinics planning a 
phased return to normal clinical services should prioritise older women and those with a known cause 
of infertility. 
STUDY FUNDING/COMPETING INTEREST(S): No external funding was received for this study. B.W.M. 
is supported by an NHMRC Practitioner Fellowship (GNT1082548) and reports consultancy work for 
ObsEva, Merck, Merck KGaA, Guerbet and iGenomics. SB is Editor-in-Chief of Human Reproduction 
Open. None of the other authors declare any conflicts of interest.
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Introduction
IVF is the recommended treatment for those with prolonged unresolved infertility regardless of the 
underlying cause (NICE, 2023), with a total of just under 70,000 treatment cycles offered across the 
UK in 2017/18 (HFEA, 2020a). The coronavirus disease 2019 (COVID 19) pandemic had triggered a 
worldwide suspension of fertility treatments, including all planned IVF in the UK since March 2020. 
Key reasons behind this have been uncertainty about the impact of COVID 19 on pregnancy, a desire 
to reduce the burden of non-essential treatments during a national lockdown and the need to release 
clinical staff and resources from the fertility sector to deal with the pressing demands of COVID-related 
health problems. 
Now that national measures to reduce person to person transmission have succeeded in decreasing 
rates of infection, emerging health data are starting to reveal the negative impact of prioritising COVID 
19 pathways over other clinical areas (AOMRC, 2020) and the UK National Health Service and other 
health care systems are now planning a recovery phase for fertility clinics (HFEA 2020b). While patients 
are keen to access IVF and clinics want to treat them as quickly as possible, several months of inactivity 
have resulted in a sizeable backlog of untreated couples.  The volume of activity within each IVF clinic 
is likely to be reduced by the demands of social distancing and the need to build resilience within the 
clinical team to cope with staff illness (ESHRE, 2020) and further periods of lockdown.  While it is 
logistically easier to treat the patients in accordance with their position on a waiting list, this may not 
maximise the net health gain for the individuals, funders and society. Given the significant negative 














policy of prioritising older women in their 40s and late 30s could be helpful for this group but carries 
a risk of compromising outcomes in younger women forced to wait for several months for treatment.  
It is therefore critical that any plans to restart fertility treatment are based on a prioritisation system, 
which aims to identify women who should be treated early in a manner that does not disadvantage 
those who may need to wait longer.  Factors such as increased female age and a longer duration of 
pregnancy, which can compromise treatment success (Templeton et al. 1996; Lawlor and Nelson 2012; 
McLernon et al. 2016), and unexplained infertility, which is compatible with a reasonable chance of 
natural pregnancy (Brandes et al. 2011; Bhattacharya et al. 2008), need to be taken into account in 
assessing the net benefit of IVF in this group. Alviggi et al, (2020) have recently proposed using female 
age, ovarian reserve and previous history of ovarian stimulation to stratify women undergoing IVF into 
prognostic groups based on their chances of live birth. Apart from this, there is very little evidence in 
the literature to inform a prognosis-based  plan for prioritising IVF treatment either at the national or 
individual clinic level.
We have previously developed a prediction model based on national IVF data (McLernon et al. 2016) 
to predict the chance of pregnancy leading to live birth over one or more complete cycles of IVF. This 
can be adapted to estimate the impact of delaying the start of treatment by 6 or 12 months. Any such 
estimate also needs to consider the chance of treatment-independent pregnancy in infertile couples 
with no identifiable barrier to conception using a separate prediction model (van Eekelen et al. 2017). 
The aim of this study was to adapt these existing fertility prediction models to estimate the impact of 
delayed treatment on the chances of live birth in different groups of women seeking IVF, based on 















The Human Fertilisation and Embryology Authority (HFEA) collects data on all licensed fertility 
treatments in the UK. A detailed version of the HFEA database is available for research purposes under 
strict conditions, which links all IVF treatments to complete cycles and to individual women and allows 
estimation of the cumulative probability of a live birth (McLernon et al. 2016). Following approval by 
the North of Scotland Research Ethics Committee, the Confidentiality Advisory Group, and the HFEA 
register research panel, anonymised data from 2017 on all treatments linked to each woman 
undergoing IVF or ICSI were made available to the authors.
Study population
Linked data were extracted on consenting women who underwent their first complete IVF and ICSI 
cycle between January 2017 and December 2017 in the UK. A complete IVF cycle comprised a single 
episode of ovarian stimulation followed by replacement of all fresh and frozen embryos created from 
the oocytes retrieved.  Women treated with non-autologous gametes, such as donor insemination, 
egg donation, and surrogacy, were excluded. 
Statistical analysis
We used a prediction model we had developed earlier (McLernon et al. 2016) to estimate the 
probability of live birth over a complete IVF cycle in women who started IVF treatment in 2017.  For 
each woman, we estimated outcomes at three time points – immediate treatment, a 6-month delay 
and a 12-month delay.  This model uses the following characteristics: female age, duration of 
infertility, previous pregnancy status, IVF or ICSI treatment, and cause of infertility to calculate the 
chance of live birth over one complete cycle of IVF. 
The predictions were initially calculated using data from women who had consented for research. The 














groups 40-42, 38-39, 36-37, 30-35 and < 30 years. For predictions associated with a delay in initiating 
treatment, we added an extra 6 or 12 months to both age and duration of infertility. In women with 
unexplained infertility, who have no absolute barrier to conception, we assumed that some would 
conceive whilst waiting for treatment. To obtain the predicted probability of natural conception 
leading to live birth in the 2017 patients, we applied a model developed from a cohort of Dutch 
couples with unexplained infertility (van Eekelen et al. 2017) and externally validated in a Scottish 
population (van Eekelen et al. 2018). From the point of completion of a couple’s diagnostic work up, 
this model can estimate natural conception over different time periods based on the predictors female 
age, duration of infertility, primary versus secondary infertility, sperm motility and mode of referral 
for specialist fertility care (general practitioner versus gynaecologist). Since the last two variables were 
unavailable in our dataset, we assumed  a normal sperm motility of 32% (Barratt et al. 2017) and 
referral by a general practitioner. To estimate the probability of natural conception over 6 months, 
we assumed that women with unexplained infertility would receive IVF on average 1 year after 
completion of their diagnostic workup. This was derived from women’s median duration of infertility 
at the start of IVF (3 years) (Table I) less the median duration of infertility (2 years) at workup 
completion in a UK cohort (Mclernon et al, 2019). Thus, to derive the woman’s age and duration of 
subfertility at the time of completion of the diagnostic workup, we subtracted 12 months from their 
age and duration of infertility at the time of starting IVF. As this model updated predictions at repeated 
time points, we used it to generate predictions from 1 year after completion of diagnostic workup – 
to reflect the time between diagnosis and the start of IVF treatment. We then predicted the chance 
of natural conception leading to ongoing pregnancy over the next 6 and 12 cycles that represent the 
6- and 12-month delay in treatment. Ongoing pregnancy was defined as the presence of foetal cardiac 
activity at transvaginal sonography at a gestational age of at least 12 weeks. Since the dynamic model 
predicts natural conception leading to ongoing pregnancy, we converted these probabilities to the 
predicted probability of live birth by multiplying them by 0.95 (Braakhekke et al. 2014). This assumes 














For women with other causes of infertility we used two different estimates for their chance of 
conceiving naturally. The first was a conservative assumption where we allocated all of these women 
with a zero chance of conceiving naturally. The second was an optimistic estimate, which was obtained 
through application of a model developed using a prospective cohort of Dutch couples with different 
causes of infertility who were registered on a national waiting list for IVF (Eijkemans et al, 2008). This 
model can estimate natural conception over 1 year based on the predictors female age, duration of 
infertility, primary versus secondary infertility, and cause of infertility. In order to apply this model to 
our dataset we had to estimate the baseline survival at 6 months and 12 months because this 
information was not reported in the original article. However, a later article that provided predictions 
for women with different characteristics using this model allowed us to estimate the baseline survival 
at 12 months (Eijkemans et al, 2017). To calculate predicted probabilities at 6 months we multiplied 
the 12-month predictions by 0.6 (van Eekelen et al, 2017).
We incorporated these chances into the overall impact on delayed IVF using the following equation:
Predicted probability of live birth with Delayed IVF, Pdelay = PNC + (1- PNC) X PIVF
where PNC = Predicted probability of conception during delay leading to live birth; and PIVF = Predicted 
probability of live birth over one complete cycle of IVF which starts after the delay.
Where there was no delay (i.e. immediate IVF), PNC = 0.
The difference in live birth predictions between each delay period and immediate treatment were 
calculated for all women in the linked consented HFEA dataset, then averaged for different causes of 
infertility and age groups of women. As well as the difference in predictions between scenarios, we 














When we applied our original IVF prediction model (Mclernon et al, 2016) to the 2017 data the C-
statistic was 0.60 (0.59 to 0.61). The calibration intercept was -0.58 (95% CI: -0.63 to -0.52) and the 
calibration slope was 0.78 (0.70 to 0.87) suggesting that the model did not fit well to the 2017 dataset 
(Supplementary Fig. S1a). Therefore, the model was recalibrated by multiplying the parameter 
estimates in the model equation by the calibration slope and then adding the calibration intercept. 
After recalibration the model showed much better agreement (Supplementary Fig. S1b). 
Ethics 
Access to the linked anonymised HFEA database for this study was approved by the North of Scotland 
Research Ethics committee (12/NS/0119) and the HFEA Research Registry Panel.
Patients and the public were not involved in designing this study, analysing the results or writing this 
paper.
Results
A total of 24,839 couples underwent their first IVF or ICSI treatment in 2017. After excluding women 
who did not provide consent for their data to be used for research, our linked anonymised version of 
the HFEA dataset included 11,575 couples.  We excluded 1,039 couples with no recorded cause of 
infertility and 947 couples with more than one cause of infertility. This left 9,589 couples whose 
characteristics are shown in Table I. The profile of women whose linked data were used to calculate 
our predictions resembled that of the whole population embarking on IVF in 2017 (Supplementary 
Table SI).
Table II shows the predicted probability for immediate treatment versus a 6-month delay in IVF or ICSI 
in women of different age groups. A 6-month delay in access to a complete IVF cycle was estimated 














(9.5%) and  1.5%  (11.8%)  in women aged <30, 30-35, 36-37, 38-39 and 40-42 years, respectively. 
Table II also shows the corresponding absolute and relative percentage reduction in the chance of live 
birth caused by delaying the start of treatment by 12 months to be 0.3% (0.9%), 1.6% (4.9%), 3.2% 
(11.9%), 3.8% (18.8%) and 2.9% (22.4%) for those same age groups.
Table III compares the outcomes of immediate treatment with those associated with a 6-month delay 
in hypothetical women with no previous pregnancy and a 2-year duration of infertility. For example, 
in a 30-year-old woman with tubal infertility, the chance of an IVF live birth falls from 31.5% if treated 
immediately to 31.1% if treated at 6 months in the conservative scenario, where we assume that she 
has no chance of conceiving naturally during those 6 months. However, an optimistic scenario predicts 
her chances of a live birth to be as high as 34.3% if treated at 6 months. In a 30-year-old woman with 
unexplained infertility, the chance of an IVF live birth falls from 34.2% if treated immediately, to 33.8% 
if treated after 6 months. However, this is more than compensated by a 10.2% chance of treatment 
independent pregnancy whilst waiting, such that overall predicted chance of a live birth following 
delayed treatment is 40.6%. The corresponding predictions associated with a 12-month delay in 
hypothetical women are presented in Table IV.
Tables V and VI report on predicted chances of live birth in women with unexplained as well as other 
types of infertility.  In women with infertility associated with tubal disease, endometriosis, male factor 
or ovulatory disorders, if the chances of conceiving naturally are assumed to be nil, the impact of delay 
on predicted live birth worsens in women from the age of 30 years (Tables V and VI). A more optimistic 
approach reverses this trend, but the effect is modest in all except women under 35 years. 
In women with tubal infertility, conservative (optimistic) chances of predicted live birth rates after a 
6-month delay are 31.6% (35.0%), 29.0% (31.6%), 23.1% (25.2%), 17.2% (19.4%), and 10.3% (12.3%) 














corresponding live birth rates associated with immediate treatment are 31.7%, 29.8%, 24.5%, 19.0%, 
and 11.7% in the corresponding age groups.
In women with endometriosis facing a delay of 6 months, even an optimistic approach is unable to 
show an increase in live birth rates in women over 35 years (Table V). While the absolute chances of 
live birth range from a 0.8% reduction to a 1.0% increase in women aged 30-35 years, for those aged 
40-42 years the same delay would cause an absolute decrease ranging from -0.5% to -1.9% (see Table 
V). 
A 12-month wait is associated with a fall in the anticipated live birth rate - from 31.5% to 29.8% in 
women with endometriosis aged 30-35 and 12.4% to 9.6% in those aged between 40 and 42 years 
(Table VI). An optimistic estimate improves the chance of live birth by 1.4% in women aged 30-35 
years, but not for those who are older (Table VI).
In women with tubal infertility, a 12-month delay is associated with a decrease in the chance of live 
birth from 29.8% to 28.3% in those aged 30-35 and 11.7% to 9.1% in those aged between 40 and 42 
years, assuming a 0% chance of natural pregnancy (Table VI). However, an optimistic prediction would 
see these chances increase to 32.5% and 12.4%, respectively. 
In women with unexplained infertility, the negative impact of a delay in starting IVF is compensated 
by the chance of conceiving without treatment whilst waiting. Thus, the predicted chance of a live 
birth in those facing a 6-month wait, which includes the chance of conceiving naturally during those 6 
months followed by the chance of conceiving with IVF, is 36.6% in women aged 30-35 years and 15.1% 
in women aged 40-42 years compared to 32.5% and 13.2% in women treated without any delay. (Table 
V). A 12-month delay shows similar projections, with a live birth rate of 39.4% in women aged 30-35 

















Our results show that delaying the start of IVF by 6 or 12 months has relatively little impact on the 
chances of live birth in younger women but substantially compromises outcomes in women over 40 
years of age. In those with unexplained infertility, a delay of up to 1 year may not be detrimental as 
couples can conceive whilst waiting for treatment, with IVF being available later for all those who do 
not. This holds true for older women as well, although the additional benefit is small in those who 
wait. In other types of infertility, predictions assuming no chance of natural pregnancy suggest 
compromised outcomes in all those who have to wait 6 or 12 months. A more optimistic prediction, 
which is based on the expectation of some treatment independent conceptions whilst waiting for IVF 
or ICSI, show a modest rise associated with delay, especially in younger women. 
Strengths and weaknesses
This is the first study to use national data to predict the consequences of delaying the start of IVF in 
different groups of women, whilst incorporating the chances of natural pregnancy in couples with 
different categories of infertility. This is a critical step in assessing the additional value of IVF (NICE, 
2013) but is often missing in previous studies, as is the use of a model that can estimate live birth after 
a complete cycle (McLernon et al.2016). 
This study has several limitations. Our predicted live birth rates need to be validated in prospective 
studies to confirm their accuracy. Major sources of uncertainty include the use of prediction models 
generated in different populations and the need for a number of assumptions. Although the models 
are validated and the bases for the assumptions are robust, it is impossible to eliminate the possibility 
of imprecision in our predictions.  We have combined IVF and its variant ICSI in a single model under 














work has reported slight differences in outcomes between the two (Lawlor and Nelson 2012).  As ICSI 
has not been shown to be more effective than IVF for non-male infertility and is not recommended 
for any other situations (NICE,2013), this approach should not compromise our predictions in the 
unexplained cohort where this diagnosis has been excluded.
Another potential weakness is the fact that we were only able to use linked data from consenting 
couples for our predictions, although the characteristics of participants do not appear to be different 
to those of the complete cohort. As data for 2020 are not yet available, our predictions for those facing 
IVF treatment delay are based on couples treated in 2017.  
In conditions other than unexplained infertility, we have assumed the chances of natural conception 
to range between nil and an optimistic value obtained from a prognostic model (Eijkemans et al, 2008; 
Eijkemans et al, 2017). This is because a small proportion of women with other causes, such as 
unilateral tubal block, endometriosis, irregular ovulation and partners with deranged semen 
parameters, have been known to get pregnant without treatment (Arce et al. 2005; Collins et al. 1995) 
but these chances are generally perceived to be  low enough to recommend active treatment rather 
than an expectant approach (NICE, 2013).
Findings in context of the literature
Our results are consistent with the conclusions of previous studies (Ratna et al. 2020; van Eekelen et 
al. 2018; van Loendersloot et al. 2010; van Loendersloot et al. 2014), which have all highlighted the 
importance of female age and duration of infertility in determining the chances of success following 
IVF treatment. The impact of age is likely to be mediated by its effect on ovarian reserve but recent 
data from women with diminished ovarian reserve suggest that delaying the start of IVF by up to 180 














Less well researched, owing to the paucity of relevant data, is the chance of natural conception in 
untreated couples with unexplained infertility. Limited data from the literature indicate that couples 
who have been trying for a relatively short duration have a good chance of natural conception and 
thus may not benefit from immediate access to IVF (Brandes et al. 2011).  Few previous models have 
been able to compare individualized chances of conception associated with IVF relative to chances of 
natural conception in the same population (van Eekelen et al. 2019). Those which have done so have 
reported live birth outcomes in couples embarking on a strategy of expectant management or IVF 
without the ability to report separately on the chances of treatment- related and treatment-
independent pregnancies at different points in time (Barratt et al. 2017).  The predicted live birth rates 
in our study may appear optimistic, but it is worth noting that these not only include the chance of 
natural conception whilst waiting, but also the additional benefit of IVF in those who start treatment 
at 6 or 12 months. As such they are not inconsistent with the 24.5% (95% CI: 20-29%) chance of natural 
conception over 12 months in a randomised cohort of couples (van Eekelen et al. 2018) or a 17% 
chance of natural live birth over 5 years following unsuccessful IVF treatment (Romanski et al. 2020).
The literature contains few recent studies on natural chances of conception in couples with known 
causes of infertility. A prospective cohort study on Dutch couples awaiting IVF or ICSI in The 
Netherlands showed that although the chances of treatment-independent pregnancy were lower in 
this group they were not insignificant (Eijkemans et al, 2008). The likelihood of natural conception 
varied according to the type of infertility, and provided the basis for our optimistic predictions of 
natural pregnancy in this group.
Our primary aim was to investigate the impact of delaying treatment in different groups of couples 
registered to start IVF in order to inform a strategy for sequencing treatment in the post pandemic 
recovery period. The results are therefore not comparable to those from studies modelling the 
chances of live birth following immediate IVF compared to a 1-year delay (El Mokhallalati et al. 2019). 














different waiting times for access to IVF. Our analysis therefore focuses on the period between the 
decision to have IVF and the start of treatment and does not mandate a similar time horizon for follow-
up for all couples. This approach disregards the chance of natural conception following unsuccessful 
IVF in those who have immediate treatment as our question was formulated to aid decision making 
around starting IVF rather than to explore the value of IVF in couples with unexplained infertility. From 
a clinical perspective, the answer is unlikely to influence decision making in couples already committed 
to active treatment.
From a methodological point of view, any assumptions around the appropriate time horizon for follow 
up will be imprecise as the length of time needed for a complete cycle of IVF treatment is variable. In 
addition, the use of our dynamic model, which was developed to estimate pre-treatment natural 
conception, may not be valid for predictions in a post IVF cohort of couples in whom the chance of 
conceiving naturally after failed IVF may be lower.
Clinical implications
We anticipate that our results will help to inform a process of phased access to IVF in a post COVID 19 
recovery period.  The estimates of live birth in different categories of infertile women is expected to 
help patients understand the rationale for decisions made by clinics, funders and policy makers in 
formulating a strategy for re-starting IVF treatment. 
Our predicted estimates show that older women, particularly those with a low chance of natural 
conception, are at highest risk if left untreated for 6 months or more. Whilst the impact is highest on 
women over 40 years, this is true for women in their mid and early thirties with known causes of 














The situation is different in couples with unexplained infertility whose background rate of natural 
conception can offset any reduction in IVF success rates associated with a delay of 6-12 months.  Our 
estimates show an age-linked trajectory, with greater gains in younger women. As with all predictions, 
these values need to be interpreted with caution and while this information may be reassuring for 
some patients, others might feel that a policy of deferred treatment does not acknowledge their 
personal preferences. Previous research has revealed that many in this group tend to find an 
expectant approach frustrating and seek to commence early treatment (Kersten et al. 2017; van den 
Boogaard et al, 2011). 
It is worth noting that in couples who fail to conceive during the waiting period of 6-12 months, the 
delay will impact on their future chances of live birth. As most couples are unlikely to conceive after 
their first complete cycle of IVF, this delay is likely to have consequences for the cumulative chances 
of having a baby over a series of treatments.
Our results challenge the current policy of applying access criteria based on a fixed duration of 
unexplained infertility for couples with different prognostic profiles  (NICE, 2013) and support recent 
guidance (RCOG, 2020) advising earlier hospital appointments for older women. In addition to 
prognostic profiles, individual clinics may have to consider the size of their backlog, anticipated volume 
of activity and the proportion of women in different age and diagnostic categories in order to prioritise 
access to treatment.
Research recommendations
This research exposes the limitations of the literature in providing a robust evidence base for 
individualised, prognosis-based decision making in assisted reproduction and the limitations of 
interpreting IVF success rates in couples with unexplained infertility without factoring in the chance 














comparing IVF with expectant management (Pandian et al, 2015), future research should focus on 
large population-based studies, which can generate data on conception with and without IVF. Further 
refinement of dynamic models, which allow repeated predictions over time, are needed to inform 
decisions to transition from an expectant approach to active treatment. This can only be possible 
through widespread use of general fertility registries, which are rare in comparison with IVF data 
collection systems.
Conclusion
Delay reduces IVF success rates in all couples. This results in a lower chance of live birth in older 
women, especially those with a known cause of infertility. In women with unexplained infertility, the 
impact of delay is more than compensated by the chance of natural conception during a 6-12month 
treatment-free interval. In the post COVID 19 recovery period, clinics planning a phased return to 
normal clinical services should prioritise older women, particularly those with a known cause of 
infertility. 
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Figure legends
Supplementary Figure S1 Calibration plots showing the association between the predicted probability 
of live birth and observed proportion of live births over the first complete cycle of IVF in women who 
started their treatment in 2017.
 Predicted probability of live birth and observed proportion of live births for (a) the original pre-
treatment model as described by McLernon et al. (2016) applied to women who started IVF in 2017 
and (b) recalibrated pre-treatment model with adjustment of the intercept and the slope applied to 
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Table I Characteristics of women who started IVF treatment in 2017.
Characteristic N (%)
Number of patients 9589
Female age (years), mean (SD) 34.1 (4.0)
Duration of infertility (years), median (IQR) 3 (2-6)
Previous pregnancy Yes 3885 (40.5)
No 5704 (59.5)
Cause of infertility Tubal 921 (9.6)
Endometriosis 523 (5.5)
Unexplained 4037 (42.1)
Male factor 3235 (33.7)
Anovulation 873 (9.1)
Treatment type IVF 5018 (52.3)
ICSI 4571 (47.7)
IQR: interquartile range
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Table II Predicted chance of live births by age group for immediate treatment versus 6-month delay in IVF or ICSI *.
Scenario 1: Treat 
now






chance of live birth 
(%)
Average predicted 














% change in 
average 
chance 
<30 1370 34.2 34.1 -0.1 -0.4 33.9 -0.3 -0.9
30-35 4520 32.1 31.3 -0.8 -2.4 30.5 -1.6 -4.9
36-37 1478 26.6 25.1 -1.5 -5.6 23.4 -3.2 -11.9
38-39 1328 20.4 18.4 -1.9 -9.5 16.5 -3.8 -18.8
40-42 893 12.9 11.4 -1.5 -11.8 10.0 -2.9 -22.4
* using only predictions from the OPIS IVF model (McLernon et al 2016)
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Table III Example of predictions considering a 6-month delay for women undergoing IVF with no previous pregnancy and 2 years duration of infertility.





Delay by 6 months†
Difference in 
chance†
% Chance of 
IVF live birth, 
Pimmediate¶
% Chance of natural 
conception over 6 
months, PNC_6m
% Chance of IVF 
live birth if begin 
in 6 months, 
PIVF_6m
% Chance of live 
birth if delay IVF 




  Unexplained 30 34.2  10.2 33.8  40.6   +6.4
35 29.6   7.8 28.6  34.2   +4.6
40 15.3   5.5 13.5  18.3   +3.0
Endometriosis 30 33.2   0.0 to 3.4 32.8  32.8 to 35.1  -0.4 to +1.9
35 28.6   0.0 to 2.6 27.7  27.7 to 29.6  -1.0 to +0.9
40 14.7   0.0 to 2.1 13.0  13.0 to 14.8  -1.7 to +0.1
  Anovulatory 30 34.0   0.0 to 5.4 33.6  33.6 to 37.2  -0.4 to +3.2
35 29.4   0.0 to 4.2 28.4  28.4 to 31.5  -1.0 to +2.0
40 15.2   0.0 to 3.3 13.4  13.4 to 16.3  -1.7 to +1.1
        Tubal 30 31.5   0.0 to 4.6 31.1  31.1 to 34.3  -0.4 to +2.8
35 27.1   0.0 to 3.6 26.2  26.2 to 28.8  -0.9 to +1.7
40 13.8   0.0 to 2.8 12.2  12.2 to 14.6  -1.6 to +0.8
  Male factor 30 31.4   0.0 to 7.0 31.1  31.1 to 35.9  -0.4 to +4.5
35 27.1   0.0 to 5.5 26.1  26.1 to 30.2  -0.9 to +3.1
40 13.7   0.0 to 4.3 12.1  12.1 to 15.9  -1.6 to +2.2
¶ Predicted probability of live birth over the first complete cycle of IVF (i.e. fresh and/or frozen embryo transfers associated with first egg retrieval).
† For causes of infertility that are not unexplained, the conservative and optimistic range is given. The conservative prediction for natural live birth is 0% 
while the optimistic is calculated from a prediction model (Eijkemans et al, 2008).
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± Cumulative chance of conceiving naturally over 6-month delay and following one complete cycle of IVF.
Table IV Example of predictions considering a 12-month delay for women undergoing IVF with no previous pregnancy and 2 years duration of infertility.





Delay by 12 months†
Difference in 
chance†
% Chance of 
IVF live birth, 
Pimmediate¶
% Chance of natural 
conception over 12 
months, PNC_12m
% Chance of IVF live 
birth if begin in 12 
months, PIVF_12m
% Chance of live 
birth if delay IVF 




  Unexplained 30 34.2  17.6 33.3  45.1  +10.9
35 29.6  13.6 27.5  37.3   +7.7
40 15.3   9.7 11.9  20.4   +5.2
Endometriosis 30 33.2   0.0 to 5.7 32.3  32.3 to 36.1  -0.9 to +2.9
35 28.6   0.0 to 4.4 26.6  26.6 to 29.8  -2.1 to +1.2
40 14.7   0.0 to 3.4 11.4  11.4 to 14.5  -3.2 to -0.2
  Anovulatory 30 34.0   0.0 to 9.0 33.1  33.1 to 39.2  -0.9 to +5.2
35 29.4   0.0 to 7.1 27.3  27.3 to 32.4  -2.1 to +3.0
40 15.2   0.0 to 5.5 11.8  11.8 to 16.7  -3.3 to +1.5
        Tubal 30 31.5   0.0 to 7.7 30.7  30.7 to 36.0  -0.9 to +4.5
35 27.1   0.0 to 6.0 25.1  25.1 to 29.6  -2.0 to +2.5
40 13.8   0.0 to 4.7 10.7  10.7 to 14.9  -3.1 to +1.1
  Male factor 30 31.4   0.0 to 11.7 30.6  30.6 to 38.7  -0.9 to +7.3
35 27.1   0.0 to 9.2 25.0  25.0 to 32.0  -2.0 to +4.9
40 13.7   0.0 to 7.2 10.7  10.7 to 17.1  -3.1 to +3.4
¶ Predicted probability of live birth over the first complete cycle of IVF (i.e. fresh and/or frozen embryo transfers associated with first egg retrieval).
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† For causes of infertility that are not unexplained, the conservative and optimistic range is given. The conservative prediction for natural live birth is 0% 
while the optimistic is calculated from a prediction model (Eijkemans et al, 2008).
± Cumulative chance of conceiving naturally over 12-month delay and following one complete cycle of IVF.
Table V Predicted chance and number of live births by cause of infertility and age group for immediate versus 6-month delay in IVF.
Scenario 1: Treat 
now






of live birth (%)
Average 
predicted 
chance of live 
birth (%)
Difference in average 
chance 
(Scenario 2 – Scenario 1)
Percentage change in chance
(Difference / Scenario 1)*100
  Unexplained   <30 432 34.9  41.0   +6.1  +17.5
30-35 1858 32.5  36.6   +4.1  +12.6
36-37 654 26.9  29.4   +2.5   +9.1
38-39 635 20.7  22.4   +1.7   +8.4
40-42 458 13.2  15.1   +1.8  +13.8
Endometriosis   <30 56 33.5  33.3 to 35.6  -0.1 to +2.1  -0.4 to +6.4
30-35 268 31.5  30.7 to 32.5  -0.8 to +1.0  -2.5 to +3.3
36-37 81 25.8  24.3 to 25.8  -1.5 to -0.0  -5.9 to -0.0
38-39 81 19.9  18.0 to 19.4  -1.9 to -0.5  -9.5 to -2.5
40-42 37 12.4  10.9 to 12.2  -1.5 to -0.2 -11.9 to -1.5
  Anovulatory   <30 171 34.6  34.5 to 38.1  -0.1 to +3.5  -0.4 to +10.2
30-35 442 32.4  31.7 to 34.5  -0.7 to +2.1  -2.3 to +6.3
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36-37 120 27.1  25.6 to 28.1  -1.5 to +1.0  -5.4 to +3.6
38-39 95 20.9  18.9 to 21.3  -2.0 to +0.4  -9.4 to +1.8
40-42 45 13.3  11.7 to 14.1  -1.6 to +0.8 -11.8 to +6.1
        Tubal   <30 150 31.7  31.6 to 35.0  -0.1 to +3.3  -0.3 to +10.4
30-35 443 29.8  29.0 to 31.6  -0.7 to +1.8  -2.4 to +6.1
36-37 149 24.5  23.1 to 25.2  -1.4 to +0.7  -5.8 to +2.7
38-39 112 19.0  17.2 to 19.4  -1.8 to +0.3  -9.6 to +1.7
40-42 67 11.7  10.3 to 12.3  -1.4 to +0.6 -11.9 to +4.7
  Male factor   <30 561 34.4  34.3 to 39.2  -0.1 to +4.8  -0.4 to +14.0
30-35 1509 32.4  31.6 to 35.3  -0.8 to +3.0  -2.3 to +9.2
36-37 474 26.7  25.2 to 28.5  -1.5 to +1.8  -5.7 to +6.6
38-39 405 20.2  18.3 to 21.3  -1.9 to +1.1  -9.5 to +5.4
40-42 286 12.8  11.3 to 14.1  -1.5 to +1.4 -11.8 to +10.7
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Table VI Predicted chance and number of live births by age group and severity of infertility for immediate treatment versus 12-month delay in IVF.
Scenario 1: Treat 
now






of live birth (%)
Average 
predicted 
chance of live 
birth (%)
Difference in average 
chance  
(Scenario 3 – Scenario 1)
Percentage change in chance
(Difference / Scenario 1)*100
  Unexplained   <30 432 34.9  45.3  +10.4  +29.9
30-35 1858 32.5  39.4  +6.9  +21.4
36-37 654 26.9  30.9   +3.9 +14.6
38-39 635 20.7  23.4   +2.8  +13.5
40-42 458 13.2  16.3   +3.1  +23.4
Endometriosis   <30 56 33.5  33.1 to 36.9  -0.3 to +3.5  -1.0 to +10.4
30-35 268 31.5  29.8 to 32.9  -1.6 to +1.4  -5.1 to +4.5
36-37 81 25.8  22.6 to 25.2  -3.2 to -0.6 -12.3 to -2.4
38-39 81 19.9  16.1 to 18.5  -3.7 to -1.4 -18.8 to -6.8
40-42 37 12.4   9.6 to 11.8  -2.8 to -0.6 -22.6 to -5.0
  Anovulatory   <30 171 34.6  34.3 to 40.4  -0.3 to +5.8  -0.9 to +16.8
30-35 442 32.4  30.9 to 35.6  -1.5 to +3.2  -4.8 to +9.8
36-37 120 27.1  24.0 to 28.1  -3.1 to +1.1 -11.4 to +3.9
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38-39 95 20.9  17.0 to 21.0  -3.9 to +0.1 -18.6 to +0.6
40-42 45 13.3  10.3 to 14.3  -3.0 to +1.0 -22.4 to +7.9
        Tubal   <30 150 31.7  31.5 to 37.1  -0.2 to +5.4  -0.8 to +17.2
30-35 443 29.8  28.3 to 32.5  -1.5 to +2.8  -5.0 to +9.2
36-37 149 24.5  21.5 to 25.1  -3.0 to +0.6 -12.1 to +2.3
38-39 112 19.0  15.4 to 19.1  -3.6 to 0.0 -19.0 to +0.3
40-42 67 11.7   9.1 to 12.4  -2.7 to +0.6 -22.7 to +5.4
  Male factor   <30 561 34.4  34.1 to 42.4  -0.3 to +8.0  -0.8 to +23.1
30-35 1509 32.4  30.8 to 37.1  -1.6 to +4.7  -4.9 to +14.6
36-37 474 26.7  23.5 to 29.1  -3.2 to +2.4 -12.0 to +9.0
38-39 405 20.2  16.4 to 21.6  -3.8 to +1.3 -18.8 to +6.6
40-42 286 12.8   9.9 to 14.8  -2.9 to +2.0 -22.5 to +15.7
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